Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0

  Measured over: Safety will be assessed up to the follow-up period, approximately 24 months.

• Part 1: Ocurrence of dose-limiting toxicities (DLTs)

  Measured over: Safety will be assessed up to the follow-up period, approximately 24 months.

• Part 1: Changes from baseline in laboratory parameters

  Measured over: Safety will be assessed up to the follow-up period, approximately 24 months.

• Part 1: Changes from baseline in vital signs

  Measured over: Safety will be assessed up to the follow-up period, approximately 24 months.

• Part 1: Changes from baseline in electrocardiogram (ECG) results

  Measured over: Safety will be assessed up to the follow-up period, approximately 24 months.

• Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)

  Measured over: (Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months

Changes Tremor has spotted